Used in research and development for targeting fucosylated GM1 gangliosides expressed on certain tumor cells, particularly small cell lung cancer (SCLC). Enables specific detection and binding to cancer cells, supporting studies in targeted therapy and immuno-oncology. Investigated for its potential in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to eliminate tumor cells. Also serves as a reference standard in assay development, biomarker validation, and preclinical evaluation of therapeutic antibodies targeting glycolipid antigens.